The U.S. Food and Drug Administration (FDA) announced Tuesday that it is amending the emergency use authorizations (EUAs) for the Pfizer-BioNTech and Moderna bivalent COVID-19 vaccines. This change allows individuals aged 65 and older, and certain immunocompromised individuals, to receive additional doses of the bivalent vaccines. These additional doses can be administered before the planned fall vaccination campaigns, offering an extra layer of protection for vulnerable populations.
The FDA's decision reflects ongoing monitoring of the virus and the effectiveness of the current vaccines. The agency stated that it will continue to evaluate data and adjust its recommendations as needed. This action aims to provide flexibility for healthcare providers to administer booster doses to individuals who may benefit most from increased protection against COVID-19, especially as new variants emerge.
While the bivalent vaccines offer protection against both the original strain and Omicron variants, immunity can wane over time. Therefore, the FDA encourages eligible individuals to consult with their healthcare providers to determine if an additional booster dose is appropriate for them. The upcoming fall vaccination campaigns are expected to address newly circulating variants and provide updated protection for the broader population.
FDA Authorizes Extra COVID Boosters for Seniors, Immunocompromised
The FDA has updated its emergency use authorization for the Pfizer and Moderna bivalent COVID-19 vaccines. Now, people 65 and older, as well as those with weakened immune systems, can receive additional booster doses. This change is meant to provide extra protection before the anticipated fall vaccination campaigns. The FDA continues to monitor the effectiveness of the vaccines against evolving variants.
Source: Read the original article at CNN